Analysis of HPV infection among 8 944 females of health examination in West China Hospital of Sichuan University_Chinese Journal of Evidence-Based Medicine

Authors：

YANG Lian , LU Xiaojun , YE Yuanxin , ZHOU Yi , WANG Xuemei ,  YING Binwu

Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R.China;

Corresponding?author：

YING Binwu, Email: binwuying@126.com

Keywords：

Human papillomavirus; Genotype; Female; Health examination; Vaccine

DOI：

10.7507/1672-2531.201611038

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate HPV infection, genotype distribution of HPV infection among 8 944 females of health examination in West China Hospital of Sichuan University. Methods We enrolled 8 944 females of health examination in West China Hospital of Sichuan University from January to September in 2016. HPV genotyping was performed by Luminex fluorescence technique. Excel 2007 and SPSS 17.0 softwares were used to analyze the infection and genotype distribution of HPV. Results The HPV infection rate of 8 944 health examination women was 14.4% (1 291/8 944). Among them, there were 1 025 cases of single infection, the infection rate was 11.5% (1 025/8 944); there were 266 cases of multiple infection, the infection rate was 3.0% (266/8 944). The infection rates of 20 to 25 years and ≥66 years groups in single and multiple infection were higher than other age groups. In the single and multiple infections, the most common genotypes were HPV52, 53, 16 and 58. Infection rate of HPV52 was the highest in single infection, which had two increased age groups including 31 to 35 years and 61 to 65 years old. Infection rate of HPV52 and HPV16 were increased in 20 to 25 years old group of multiple infections. Conclusion In view of the prevalence of HPV infection among health examination females and the genotype distribution, we recommend incorporating HPV52, 53 and 58 into future vaccine screening.

Citation： YANG Lian, LU Xiaojun, YE Yuanxin, ZHOU Yi, WANG Xuemei, YING Binwu. Analysis of HPV infection among 8 944 females of health examination in West China Hospital of Sichuan University. Chinese Journal of Evidence-Based Medicine, 2017, 17(6): 634-639. doi: 10.7507/1672-2531.201611038 Copy

1.	Crow JM. HPV: the global burden. Nature, 2012, 488(7413): S2-S3.
2.	Cancer WICOH. HPV and cervical cancer in the 2007 report. Vaccine, 2007, 25 Suppl 3: C1-C230.
3.	Wu EQ, Liu B, Cui JF, et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control, 2013, 24(4): 795-803.
4.	Jing L, Zhong X, Huang W, et al. HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study. BMC Infect Dis, 2014, 14: 388.
5.	Wang L, Wu B, Li J, et al. Prevalence of human papillomavirus and its genotype among 1336 invasive cervical cancer patients in Hunan province, central south China. J Med Virol, 2015, 87(3): 516-521.
6.	趙麗, 王文娟, 劉成桂. 成都地區人乳頭瘤病毒感染現狀及其亞型分布的回顧性分析. 四川醫學, 2016, 37(2): 135-138.
7.	馮余寬, 彭英, 朱聯, 等. 四川地區 HPV 亞型及多重感染與宮頸癌前病變的關系初探. 四川大學學報(醫學版), 2015, 43(3): 422-425.
8.	Couto E, Saeterdal I, Juvet LK, et al. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health, 2014, 14: 867.
9.	Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine, 2011, 29(11): 2011-2014.
10.	Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis, 2012, 12(10): 781-789.
11.	高婷婷, 王曉紅. 人乳頭瘤病毒疫苗研究進展. 傳染病信息, 2015, 28(2): 115-119.
12.	樊尚榮, 劉丹. 2015 年美國疾病控制中心性傳播疾病的診斷和治療指南(續)—人乳頭瘤病毒感染的診斷和治療指南. 中國全科醫學, 2015, 18(29): 3513-3515.
13.	李政, 劉繼紅. HPV 分型檢測的意義. 實用腫瘤雜志, 2010, 25(3): 233-236.
14.	方亞, 宋曉彬, 周鼒, 等. 數學模型在 HPV 疫苗經濟學評估中的研究進展. 中國衛生統計, 2014, 31(2): 348-351.
15.	Chesson HW, Flagg EW, Koutsky L, et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine, 2013, 31(29): 3019-3024.
16.	Jit M, Levin C, Brisson M, et al. Economic analyses to support decisions about HPV vaccination in low-and middle-income countries: a consensus report and guide for analysts. BMC Med, 2013, 11: 23.
17.	Woertman W, van der Wilt GJ. Estimating the effectiveness of HPV vaccination in the open population: a bayesian approach. Value Health, 2013, 16(4): 604-609.
18.	Wang R, Guo XL, Wisman GB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis, 2015, 15: 257.
19.	姜艷, 孔為民. 宮頸癌發病年輕化趨勢的研究現狀. 醫學綜述, 2012, 18(24): 4166-4169.
20.	周平, 周武, 沈默. 溫州地區女性體檢人群人乳頭狀瘤病毒感染及分布情況研究. 中國衛生檢驗雜志, 2015, 25(19): 3353-3355.
21.	Li Z, Liu F, Cheng S, et al. Prevalence of HPV infection among 28, 457 Chinese women in Yunnan Province, southwest China. Sci Rep, 2016, 6: 21039.

1. Crow JM. HPV: the global burden. Nature, 2012, 488(7413): S2-S3.
2. Cancer WICOH. HPV and cervical cancer in the 2007 report. Vaccine, 2007, 25 Suppl 3: C1-C230.
3. Wu EQ, Liu B, Cui JF, et al. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. Cancer Causes Control, 2013, 24(4): 795-803.
4. Jing L, Zhong X, Huang W, et al. HPV genotypes and associated cervical cytological abnormalities in women from the Pearl River Delta region of Guangdong province, China: a cross-sectional study. BMC Infect Dis, 2014, 14: 388.
5. Wang L, Wu B, Li J, et al. Prevalence of human papillomavirus and its genotype among 1336 invasive cervical cancer patients in Hunan province, central south China. J Med Virol, 2015, 87(3): 516-521.
6. 趙麗, 王文娟, 劉成桂. 成都地區人乳頭瘤病毒感染現狀及其亞型分布的回顧性分析. 四川醫學, 2016, 37(2): 135-138.
7. 馮余寬, 彭英, 朱聯, 等. 四川地區 HPV 亞型及多重感染與宮頸癌前病變的關系初探. 四川大學學報(醫學版), 2015, 43(3): 422-425.
8. Couto E, Saeterdal I, Juvet LK, et al. HPV catch-up vaccination of young women: a systematic review and meta-analysis. BMC Public Health, 2014, 14: 867.
9. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine, 2011, 29(11): 2011-2014.
10. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis, 2012, 12(10): 781-789.
11. 高婷婷, 王曉紅. 人乳頭瘤病毒疫苗研究進展. 傳染病信息, 2015, 28(2): 115-119.
12. 樊尚榮, 劉丹. 2015 年美國疾病控制中心性傳播疾病的診斷和治療指南(續)—人乳頭瘤病毒感染的診斷和治療指南. 中國全科醫學, 2015, 18(29): 3513-3515.
13. 李政, 劉繼紅. HPV 分型檢測的意義. 實用腫瘤雜志, 2010, 25(3): 233-236.
14. 方亞, 宋曉彬, 周鼒, 等. 數學模型在 HPV 疫苗經濟學評估中的研究進展. 中國衛生統計, 2014, 31(2): 348-351.
15. Chesson HW, Flagg EW, Koutsky L, et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine, 2013, 31(29): 3019-3024.
16. Jit M, Levin C, Brisson M, et al. Economic analyses to support decisions about HPV vaccination in low-and middle-income countries: a consensus report and guide for analysts. BMC Med, 2013, 11: 23.
17. Woertman W, van der Wilt GJ. Estimating the effectiveness of HPV vaccination in the open population: a bayesian approach. Value Health, 2013, 16(4): 604-609.
18. Wang R, Guo XL, Wisman GB, et al. Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China. BMC Infect Dis, 2015, 15: 257.
19. 姜艷, 孔為民. 宮頸癌發病年輕化趨勢的研究現狀. 醫學綜述, 2012, 18(24): 4166-4169.
20. 周平, 周武, 沈默. 溫州地區女性體檢人群人乳頭狀瘤病毒感染及分布情況研究. 中國衛生檢驗雜志, 2015, 25(19): 3353-3355.
21. Li Z, Liu F, Cheng S, et al. Prevalence of HPV infection among 28, 457 Chinese women in Yunnan Province, southwest China. Sci Rep, 2016, 6: 21039.

Chinese Journal of Evidence-Based Medicine

Analysis of HPV infection among 8 944 females of health examination in West China Hospital of Sichuan University

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content